Hospira Can't Beat Amgen's Biosimilar Notice Suit
A Delaware federal judge on Friday refused to throw out Amgen's suit accusing Hospira of improperly failing to provide 180-day notice of sales of a biosimilar version of anti-anemia blockbuster Epogen....To view the full article, register now.
Already a subscriber? Click here to view full article